

ImmunoScape

Intangibles Disclosure Framework Example Report

This is a brief analysis of ImmunoScape's Intangible Assets (IA) using the Intangibles Disclosure Framework (IDF).

The IDF outlines principles for businesses to disclose and communicate their IA such as brand value, patents or registered designs in a systematic and comprehensive way.

The disclosure principles in the IDF are anchored in four pillars: Strategy, Identification, Measurement, and Management (SIMM).

August 2024


An Overview of ImmunoScape

ImmunoScape is a preclinical-stage therapeutics company based in Singapore and San Diego, focusing on developing T cell receptor (TCR)-based immunotherapies for treating solid tumours.

The company can quickly identify functional TCR candidates through its proprietary Deep Immunomics and Machine Learning platforms, enabling it to choose the best TCRs to develop.

ImmunoScape boasts a TCR pipeline that features both risk-mitigated and innovative antigen targets, strategically positioned to address the high unmet medical need in solid tumours.

The company's therapeutic programs demonstrate superior in vitro efficacy versus clinical benchmarks and overcome conventional TCR therapy challenges, including the durability of response.





STRATEGY

Key Competitive Advantage

In light of how challenging it is to treat solid tumours, ImmunoScape introduced a novel approach (combining IP from the company and its partners) to attack cancer. Specifically, ImmunoScape offers a safe and efficacious therapeutic product that delivers a targeted and sustained strike against cancer cells.

Alignment of IA and Business Strategies for Value Creation

ImmunoScape utilises data to de-risk and realise the full value of the company's assets. In addition, ImmunoScape is exploring prospective out-licensing opportunities to further commercialise its intangible assets.

Creating Sustainable Value

Value Creation Past to Present

- **Services:** Using discovery platforms to conduct services for clinical and industry partners.
- **IP:** Retaining the exclusive ownership of the assets (TCRs) discovered in exchange for providing the biomarker data to partners and publications.
- **Transition:** Through past collaborations, utilised early method patents, workflows, etc. to build data and TCR assets that are now developing further as therapeutic candidates.

Value Creation Present to Future

- **Develop safe and efficacious drug products:** Carefully curated portfolio of T cell receptors (TCRs) and the data that surrounds the TCRs' specificity, potency and safety.
- **From services to therapeutics:** IP gives the most value as a pre-clinical therapeutic company currently conducting late-stage testing to take the lead TCR candidates into first in human trials.



IDENTIFICATION	MEASUREMENT
----------------	-------------

Key Intangibles	Metrics and Drivers
-----------------	---------------------

Technology –

Patents:

ImmunoScape has a portfolio of patents and patent applications to protect key IP incorporated in products. This includes novel T cell receptor (TCR) sequences, cellular and pharmaceutical compositions consisting of those novel TCRs, methods of diagnosing / prognosing and treating cancers and other diseases using novel TCRs, and therapies involving novel TCRs in combination with other biologics.

Trade secrets & Confidential information:

Platforms, workflows (computational algorithms), TCRs that are not yet disclosed and 'TCAPS' database (T cell information database)

Research data, business information (contracts, partnerships, development plans, employee data, etc.)

Copyrightable IP which contains appropriate markings to safeguard from any internal or external unauthorised use, e.g., Cytographer.

Metrics and Drivers

Key Milestone Indicators:

Product approval gateways (by FDA/HSA):

- Preclinical Done for ~2 candidates
- Investigational New Drug (IND) filing in 2025

Secondary Milestone Indicators:

- Technology assets: Over 100 candidates (patents filed for ~4)
- Fundraise: ~ USD 46 million
- Research Collaboration Agreements: 2 contracts (NASDAQ-listed company + SG Research Institution)
- Services: ~27 immune profiling contracts



MANAGEMENT

At ImmunoScape, the management of intangible assets is core to business strategy.

The company has put in place robust IP management processes, including clear standard operating protocols for invention disclosures and subsequent actions. In addition, IP management considerations are incorporated in contracts, e.g., inclusion of non-compete clauses in employment contracts.

ImmunoScape's IP commercialisation strategy:

- The central strategy is on heavy innovation and leveraging their technologies (IP) to discover and develop main assets, particularly TCRs for the treatment of solid cancers.
- Product development focuses on developing main candidates.
- Future products, other use cases for value capture include proprietary database, diagnostics, treating other diseases, etc.
- TCRs that are not being developed will be out licensed.



Find out more about the Intangibles Disclosure Framework [here](#).

Published by Intellectual Property Office of Singapore

This report was prepared with reference to the Intangibles Disclosure Framework, as part of the [WIPO-IPOS IP for Innovation Awards 2024](#).